Pharmaron Beijing Co., Ltd. Class A

As of June 30, 2026, Pharmaron Beijing Co., Ltd. Class H carries a market capitalization of 55.54B, placing it among publicly traded companies globally. Its enterprise value stands at 61.56B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Pharmaron Beijing Co., Ltd. Class H's next confirmed earnings release is scheduled for October 27, 2026.

As of June 30, 2026, Pharmaron Beijing Co., Ltd. Class H has 3.04B shares outstanding.

As of June 30, 2026, Pharmaron Beijing Co., Ltd. Class H trades at a trailing price-to-earnings ratio of 19.78. The price-to-sales ratio is 2.21, and the price-to-book ratio stands at 2.94.

As of June 30, 2026, Pharmaron Beijing Co., Ltd. Class H trades at an EV/EBITDA multiple of 26.96 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 26.96 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 61.56B versus a market cap of 55.54B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Pharmaron Beijing Co., Ltd. Class H maintains a current ratio of 1.02, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 40.78, indicating elevated leverage, while an interest coverage ratio of 9.81 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Pharmaron Beijing Co., Ltd. Class H posted a return on equity (ROE) of 10.98, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.06 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.27, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.63, useful for judging operating efficiency across full business cycles. The company generates approximately 715,087.93 in revenue per employee across its workforce of 24,158.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.36 indicates how many times Pharmaron Beijing Co., Ltd. Class H sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Pharmaron Beijing Co., Ltd. Class H recorded 445.12M in income tax expense. That works out to an effective tax rate of 19.66, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.26B, leaving 1.93B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Pharmaron Beijing Co., Ltd. Class H's stock has gained approximately 7.24% over the past 52 weeks. The 50-day moving average sits at 29.80, while the 200-day moving average is 22.65.

Over the twelve months ended June 30, 2026, Pharmaron Beijing Co., Ltd. Class H generated 17.28B in revenue and converted that into 1.93B in net income, yielding earnings per share of 0.87. EBITDA reached 2.28B, while operating income came in at 2.66B.

As of June 30, 2026, Pharmaron Beijing Co., Ltd. Class H holds 2.83B in cash and equivalents against 8.04B in total debt, resulting in a net debt position of 1.71B. Total book value stands at 18.90B, with working capital of 170.36M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Pharmaron Beijing Co., Ltd. Class H posted a gross margin of 34.04, reflecting its pricing power and cost economics. The operating margin of 15.37 and net profit margin of 11.17 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Pharmaron Beijing Co., Ltd. Class H paid dividends of 0.11 per share. The dividend payout ratio of 13.17 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -3.05, meaning Pharmaron Beijing Co., Ltd. Class H raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Pharmaron Beijing Co., Ltd. Class H's most recent stock split took place on July 18, 2023 with a 2:3 split ratio.

As of June 30, 2026, Pharmaron Beijing Co., Ltd. Class H has an Altman Z-Score of 3.83, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.